(Q44452834)

3 December 2017

title

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study (English)

1 reference

Fernando Rico-Villademoros

3 December 2017

0 references

0 references

1 reference

1 reference

1 reference

4

1 reference

3 December 2017

J Bobes

1

1 reference

3 December 2017

J Rejas

2

1 reference

3 December 2017

M Garcia-Garcia

3

1 reference

3 December 2017

M P García-Portilla

5

1 reference

3 December 2017

I Fernández

6

1 reference

3 December 2017

G Hernández

7

1 reference

3 December 2017

EIRE Study Group

8

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

3 December 2017

published in

Schizophrenia Research

1 reference

3 December 2017

volume

62

1 reference

3 December 2017

issue

1-2

1 reference

3 December 2017

page(s)

77-88

1 reference

The distribution of body mass index among individuals with and without schizophrenia.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Induction of obesity by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Do phase III trials have clinical value?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Dual effects of weight and weight gain on breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Body weight, weight change, and risk for hypertension in women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Mortality and weight: insured lives and the American Cancer Society studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Weight, diet, and the risk of symptomatic gallstones in middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Body weight and longevity. A reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Body Weight and Mortality among Women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

A prospective study of body mass index, weight change, and risk of stroke in women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Weight and mortality in Finnish women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Body Weight, Health, and Longevity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Bodyweight gain with atypical antipsychotics. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900431-0

7 January 2021

10.1016/S0920-9964(02)00431-0

Identifiers

DOI

1 reference

3 December 2017

1 reference